14.32
전일 마감가:
$14.20
열려 있는:
$14.39
하루 거래량:
681.40K
Relative Volume:
0.91
시가총액:
$591.97M
수익:
$128.29M
순이익/손실:
$-30.69M
주가수익비율:
-17.46
EPS:
-0.82
순현금흐름:
$-27.17M
1주 성능:
-2.05%
1개월 성능:
-42.35%
6개월 성능:
-71.53%
1년 성능:
-72.64%
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
RXST을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RXST
Rxsight Inc
|
14.32 | 591.97M | 128.29M | -30.69M | -27.17M | -0.82 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-15 | 개시 | Piper Sandler | Neutral |
2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2024-12-06 | 개시 | UBS | Buy |
2024-10-29 | 개시 | Jefferies | Buy |
2024-08-20 | 재확인 | Needham | Buy |
2024-08-06 | 재확인 | Needham | Buy |
2024-05-07 | 재확인 | BTIG Research | Buy |
2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-12-12 | 개시 | Stifel | Buy |
2023-12-04 | 개시 | Morgan Stanley | Overweight |
2023-04-13 | 개시 | Oppenheimer | Outperform |
2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
LPL Financial LLC Boosts Holdings in RxSight, Inc. (NASDAQ:RXST) - Defense World
Geode Capital Management LLC Has $28.57 Million Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Piper Sandler Initiates Coverage of RxSight (RXST) with Neutral Recommendation - Nasdaq
This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Piper Sandler Initiates RxSight at Neutral With $18 Price Target - marketscreener.com
Piper Sandler Begins Coverage of RxSight (RXST) with Neutral Rat - GuruFocus
Piper Sandler sets RxSight stock target at $18, stays neutral By Investing.com - Investing.com South Africa
Piper Sandler sets RxSight stock target at $18, stays neutral - Investing.com
Piper Sandler Starts RxSight Inc. (RXST) at Neutral - StreetInsider
RxSight price target lowered to $17 from $22 at Wells Fargo - MSN
RxSight plunges after guidance cut; BofA downgrades - MSN
RxSight stock plunges to 52-week low at $14.24 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $14.24 amid market challenges - Investing.com
UBS cuts RxSight stock rating to neutral, slashes price target to $16 By Investing.com - Investing.com South Africa
RxSight downgraded at UBS after Q1 miss and guidance cut - MSN
RxSight stock downgraded at UBS on guidance cut (RXST:NASDAQ) - Seeking Alpha
Needham Cuts Price Target on RxSight to $22 From $43, Keeps Buy Rating - MarketScreener
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45 - MarketScreener
UBS cuts RxSight stock rating to neutral, slashes price target to $16 - Investing.com Australia
UBS Downgrades RxSight Inc. (RXST) to Neutral - StreetInsider
RxSight at Needham Conference: Strategic Adjustments Amid Market Challenges By Investing.com - Investing.com Canada
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ) - The Globe and Mail
Needham & Company LLC Reiterates “Buy” Rating for RxSight (NASDAQ:RXST) - Defense World
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
Midday Stock Roundup: Masimo, Virgin Galactic an Others Take Dives - Orange County Business Journal
JP Morgan downgrades RxSight on market, competitive pressures - Investing.com
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40 - MarketScreener
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings) - Benzinga
RxSight’s preliminary Q1 2025 revenue expected to increase 28% - Medical Buyer
American Express, Rxsight, Vertiv Holdings - TradingView
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... By GuruFocus - Investing.com Canada
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 By Investing.com - Investing.com South Africa
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com
RxSight stock plunges to 52-week low at $15.84 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $15.84 amid market challenges - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight plunges after guidance cut - MSN
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock - Yahoo Finance
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of Americ - GuruFocus
BTIG cuts RxSight stock price target to $28 from $44 By Investing.com - Investing.com Australia
RxSight stock tumbles on lowered 2025 guidance By Investing.com - Investing.com Canada
RxSight (RXST) Shares Plummet After Revenue Forecast Cut - GuruFocus
RxSight stock tumbles on lowered 2025 guidance - Investing.com
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips - Investing.com Canada
BTIG cuts RxSight stock price target to $28 from $44 - Investing.com
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says - MarketScreener
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):